CARTOGEN: Optical Genome Mapping in Hematological Malignancies
Sponsor
University Hospital, Brest (Other)
Overall Status
Recruiting
CT.gov ID
NCT05009537
Collaborator
(none)
200
4
60
50
0.8
Study Details
Study Description
Brief Summary
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
200 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Optical Genome Mapping in Hematological Malignancies
Anticipated Study Start Date
:
Sep 1, 2021
Anticipated Primary Completion Date
:
Sep 1, 2022
Anticipated Study Completion Date
:
Sep 1, 2026
Outcome Measures
Primary Outcome Measures
- Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer [2021-2026]
identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH.
Secondary Outcome Measures
- identification of new chromosomal abnormalities of clinical relevance. [2021-2026]
- identification of new chromosomal anomalies involved in oncogenic pathways [2021-2026]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Minor/Major Patients
-
Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made.
-
No objection made or consent given
Exclusion Criteria:
-
Patients under judicial protection (guardianship, curatorship, ...),
-
Refusal to participate
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHRU de Brest | Brest | France | 29609 | |
| 2 | CH Morlaix, service d'hémato clinique | Morlaix | France | ||
| 3 | CHIC, service d'hémato clinique | Quimper | France | ||
| 4 | CH St Brieuc, service d'hémato clinique | Saint-Brieuc | France |
Sponsors and Collaborators
- University Hospital, Brest
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT05009537
Other Study ID Numbers:
- CARTOGEN - 29BRC21.0211
First Posted:
Aug 17, 2021
Last Update Posted:
Aug 17, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: